MedWell Ai, Inc. (OTCQB: MWAI) on Wednesday reported its quarterly financial results for the period ended March 31, 2026, revealing substantial revenue growth and improved profitability metrics. The company posted total revenue of $618,676 for the quarter, compared to $281,318 in the same period last year, representing a 120% increase. For the nine-month period, revenue reached $1.69 million, up from $425,327 in the prior year. The company also reduced its net loss to $227,939 for the quarter from $814,192, while reaffirming full-year revenue guidance of $2.3 million.
The company attributed its financial progress to the expansion of its AI-driven B2B pharma procurement operations, led by its subsidiary MedWell USA. Management noted that the company continues to lower expenses and liabilities as it scales its operations. The results were disclosed in the company's quarterly report filed with the OTC Markets Group.
Looking ahead, MedWell Ai outlined plans for its next phase of growth, including strategic acquisitions to build a vertically integrated wellness platform. The platform is expected to span biologics manufacturing, procurement services, software solutions, and back-office infrastructure. Management said the strategy is designed to capitalize on inefficiencies in healthcare procurement, drive margin expansion, and support scalable growth. For full details, the press release is available at https://ibn.fm/gLWAp.
MedWell Ai operates through three primary subsidiaries: MedWell USA, LLC, which provides B2B distribution and an e-commerce ordering portal for pharmaceutical products targeting medical offices, wellness clinics, gyms, and online telemedicine companies; MedWell Direct, LLC, doing business as TeleMD.Ai, a developer and operator of B2B/B2C telemedicine platforms connecting consumers and corporations with licensed healthcare providers; and MedWell Facilities, LLC, which focuses on real estate opportunities for health and wellness tenants and an AI-driven software platform to optimize operational models for weight loss, wellness, IV therapies, aesthetics, and traditional healthcare clinics through a licensing model.
Additional information about the company can be found on its corporate website at www.medwellai.com, its pharma procurement e-portal at www.medwellusa.com, and its telemedicine platform at www.telemd.ai (launching soon).
